膵癌・胆管癌治療薬の世界市場:開発パイプラインレビュー2018

◆英語タイトル:Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018
◆商品コード:DATA809029
◆発行会社(リサーチ会社):GBI Research
◆発行日:2018年8月
◆ページ数:385
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥415,480見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,990 ⇒換算¥830,960見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGBI Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GBI Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018
Summary

This report provides an overview of the pipeline landscape for pancreatic and bile duct cancer. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pancreatic and bile duct cancer, and features dormant and discontinued products.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas, a large gland situated in the abdominal cavity that is responsible for the secretion of digestive fluids and insulin. Signs and symptoms include upper abdominal pain, yellowing of the skin and the whites of the eyes (jaundice), loss of appetite, weight loss, depression and blood clots.

Predisposing factors include age, gender, smoking, diabetes and family history. Treatments include surgery, chemotherapy and radiation therapy. There are 759 products in development for this indication.

Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile ducts, a series of tubes in the biliary tract that are essential for the secretion of bile, which plays an important role in digestion. Symptoms include discomfort in the abdomen, loss of appetite, fevers and weight loss. Treatment includes chemotherapy and radiation therapy. There are 133 products in development for this indication.

Molecular targets acted on by products in development for pancreatic and bile duct cancer include vascular endothelial growth factor receptors, programmed cell death protein 1 and signal transducer and activator of transcription 3. Companies operating in this pipeline space include Novartis, Eli Lilly and AstraZeneca.

Scope

- Which companies are the most active within the pipeline for pancreatic and bile duct cancer?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 13
2 Introduction 14
2.1 Pancreatic and Bile Duct Cancer Report Coverage 14
2.2 Pancreatic Cancer – Overview 14
2.3 Bile Duct Cancer (Cholangiocarcinoma) – Overview 14
3 Therapeutics Development 15
3.1 Pancreatic Cancer 15
3.2 Bile Duct Cancer (Cholangiocarcinoma) 67
4 Therapeutics Assessment 81
4.1 Pancreatic Cancer 81
4.2 Bile Duct Cancer (Cholangiocarcinoma) 113
5 Companies Involved in Therapeutics Development 125
5.1 Pancreatic Cancer 125
5.2 Bile Duct Cancer (Cholangiocarcinoma) 287
6 Dormant Projects 328
6.1 Pancreatic Cancer 328
6.2 Bile Duct Cancer (Cholangiocarcinoma) 344
7 Discontinued Products 347
7.1 Pancreatic Cancer 347
7.2 Bile Duct Cancer (Cholangiocarcinoma) 351
8 Product Development Milestones 352
8.1 Pancreatic Cancer 352
8.2 Bile Duct Cancer (Cholangiocarcinoma) 369
9 Appendix 384
9.1 Methodology 384
9.2 Coverage 384
9.3 Secondary Research 384
9.4 Primary Research 384
9.5 Expert Panel Validation 384
9.6 Contact Us 385
9.7 Disclaimer 385

1.1 List of Tables
Table 1: Number of Products under Development for Pancreatic Cancer 15
Table 2: Number of Products under Development by Companies, Pancreatic Cancer 17
Table 3: Number of Products under Development by Universities/Institutes, Pancreatic Cancer 30
Table 4: Products under Development by Companies, Pancreatic Cancer 32
Table 5: Products under Development by Universities/Institutes, Pancreatic Cancer 62
Table 6: Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) 67
Table 7: Number of Products under Development by Companies, Bile Duct Cancer (Cholangiocarcinoma) 69
Table 8: Number of Products under Development by Universities/Institutes, Bile Duct Cancer (Cholangiocarcinoma) 72
Table 9: Products under Development by Companies, Bile Duct Cancer (Cholangiocarcinoma) 73
Table 10: Products under Development by Universities/Institutes, Bile Duct Cancer (Cholangiocarcinoma) 80
Table 11: Number of Products by Stage and Target, Pancreatic Cancer 82
Table 12: Number of Products by Stage and Mechanism of Action, Pancreatic Cancer 94
Table 13: Number of Products by Stage and Route of Administration, Pancreatic Cancer 110
Table 14: Number of Products by Stage and Molecule Type, Pancreatic Cancer 112
Table 15: Number of Products by Stage and Target, Bile Duct Cancer (Cholangiocarcinoma) 114
Table 16: Number of Products by Stage and Mechanism of Action, Bile Duct Cancer (Cholangiocarcinoma) 118
Table 17: Number of Products by Stage and Route of Administration, Bile Duct Cancer (Cholangiocarcinoma) 122
Table 18: Number of Products by Stage and Molecule Type, Bile Duct Cancer (Cholangiocarcinoma) 124
Table 19: Pancreatic Cancer - Pipeline by 3-V Biosciences Inc 125
Table 20: Pancreatic Cancer - Pipeline by 4P-Pharma SAS 125
Table 21: Pancreatic Cancer - Pipeline by 4SC AG 126
Table 22: Pancreatic Cancer - Pipeline by AB Science SA 126
Table 23: Pancreatic Cancer - Pipeline by AbbVie Inc 127
Table 24: Pancreatic Cancer - Pipeline by AbGenomics International Inc 128
Table 25: Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL 128
Table 26: Pancreatic Cancer - Pipeline by Aclaris Therapeutics Inc 128
Table 27: Pancreatic Cancer - Pipeline by Actuate Therapeutics Inc 129
Table 28: Pancreatic Cancer - Pipeline by Adamed Sp z oo 129
Table 29: Pancreatic Cancer - Pipeline by Aduro BioTech Inc 130
Table 30: Pancreatic Cancer - Pipeline by Advantagene Inc 130
Table 31: Pancreatic Cancer - Pipeline by AGV Discovery SAS 131
Table 32: Pancreatic Cancer - Pipeline by AIMM Therapeutics BV 131
Table 33: Pancreatic Cancer - Pipeline by Alissa Pharma 132
Table 34: Pancreatic Cancer - Pipeline by Alligator Bioscience AB 132
Table 35: Pancreatic Cancer - Pipeline by Allinky Biopharma 132
Table 36: Pancreatic Cancer - Pipeline by Altor BioScience Corp 133
Table 37: Pancreatic Cancer - Pipeline by Ambrx Inc 133
Table 38: Pancreatic Cancer - Pipeline by amcure GmbH 134
Table 39: Pancreatic Cancer - Pipeline by Amgen Inc 134
Table 40: Pancreatic Cancer - Pipeline by Amplia Therapeutics Pty Ltd 135
Table 41: Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp 135
Table 42: Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc 136
Table 43: Pancreatic Cancer - Pipeline by ANP Technologies Inc 136
Table 44: Pancreatic Cancer - Pipeline by AntiCancer Inc 136
Table 45: Pancreatic Cancer - Pipeline by APEIRON Biologics AG 137
Table 46: Pancreatic Cancer - Pipeline by Apexigen Inc 137
Table 47: Pancreatic Cancer - Pipeline by Aphios Corp 138
Table 48: Pancreatic Cancer - Pipeline by Aposense Ltd 138
Table 49: Pancreatic Cancer - Pipeline by ARMO Biosciences Inc 139
Table 50: Pancreatic Cancer - Pipeline by ArQule Inc 139

1.2 List of Figures
Figure 1: Number of Products under Development for Pancreatic Cancer 15
Figure 2: Number of Products under Development by Companies, Pancreatic Cancer 16
Figure 3: Number of Products under Development by Universities/Institutes, Pancreatic Cancer 29
Figure 4: Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) 67
Figure 5: Number of Products under Development by Companies, Bile Duct Cancer (Cholangiocarcinoma) 68
Figure 6: Number of Products under Development by Universities/Institutes, Bile Duct Cancer (Cholangiocarcinoma) 72
Figure 7: Number of Products by Top 10 Targets, Pancreatic Cancer 81
Figure 8: Number of Products by Stage and Top 10 Targets, Pancreatic Cancer 81
Figure 9: Number of Products by Top 10 Mechanism of Actions, Pancreatic Cancer 93
Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions, Pancreatic Cancer 93
Figure 11: Number of Products by Top 10 Routes of Administration, Pancreatic Cancer 109
Figure 12: Number of Products by Stage and Top 10 Routes of Administration, Pancreatic Cancer 109
Figure 13: Number of Products by Top 10 Molecule Types, Pancreatic Cancer 111
Figure 14: Number of Products by Stage and Top 10 Molecule Types, Pancreatic Cancer 111
Figure 15: Number of Products by Top 10 Targets, Bile Duct Cancer (Cholangiocarcinoma) 113
Figure 16: Number of Products by Stage and Top 10 Targets, Bile Duct Cancer (Cholangiocarcinoma) 113
Figure 17: Number of Products by Top 10 Mechanism of Actions, Bile Duct Cancer (Cholangiocarcinoma) 117
Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions, Bile Duct Cancer (Cholangiocarcinoma) 117
Figure 19: Number of Products by Routes of Administration, Bile Duct Cancer (Cholangiocarcinoma) 121
Figure 20: Number of Products by Stage and Routes of Administration, Bile Duct Cancer (Cholangiocarcinoma) 121
Figure 21: Number of Products by Top 10 Molecule Types, Bile Duct Cancer (Cholangiocarcinoma) 123
Figure 22: Number of Products by Stage and Top 10 Molecule Types, Bile Duct Cancer (Cholangiocarcinoma) 123

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[膵癌・胆管癌治療薬の世界市場:開発パイプラインレビュー2018]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆